OBJECTIVES: To retrospectively estimate the cost-effectiveness of adding zoledronic acid (ZOL; 4 mg intravenously q6m) to adjuvant endocrine therapy (ET; goserelin plus tamoxifen or anastrozole) in premenopausal women with endocrine-responsive early breast cancer (ERBC) from Italian, Spanish, and Portuguese health-care perspectives. METHODS: A Markov model projected lifetime outcomes and costs of care for ERBC patients receiving 3 years' adjuvant ET or adjuvant ET plus ZOL. Cost-effectiveness was measured as the incremental cost per quality-adjusted life-year (QALY) gained. Probabilities of BC recurrence were from the ABCSG-12 trial. Other probabilities and country-specifi c costs were from published literature. Results were generated under two scenarios: 1) benefi ts of ZOL persist to the 7-year maximum follow-up (trial benefi t); 2) benefi ts persist until recurrence or death (lifetime benefi t). RESULTS: Expected ZOL costs (medication and administration) were c1500 (Italy), c2100 (Spain), and c2300 (Portugal). Under the trial benefi t scenario, resulting savings from reduced BC recurrence partially offset costs by c900 (both Spain and Italy) and c200 (Portugal). Therefore, projected total ZOL costs were c600 (Italy), c1300 (Spain), and c2100 (Portugal). Projected QALY gains with ZOL were 0.46 (Italy), 0.47 (Spain), and 0.33 (Portugal). Costs per QALY gained were c1304 (Italy), c2766 (Spain), and c6364 (Portugal) (all favorable). Under the lifetime benefi t scenario, savings from reduced BC recurrences completely offset ZOL costs and yielded net savings of c2900 (Italy) and c2100 (Spain). Incremental total costs were c1400 for Portugal. Projected QALY gains with ZOL were 1.57 (Italy), 1.59 (Spain), and 0.96 (Portugal). The cost per QALY gained for Portugal was highly favorable (c1458). CONCLUSIONS: Adding ZOL to ET in premenopausal women with ERBC can be highly cost-effective (<c50,000 per QALY gained) in Italy, Spain, and Portugal. Additionally, ZOL would be considered cost saving to patients in Italy and Spain if these benefi ts persist >7 years. OBJECTIVES: This study aims to compare the guaiac-based fecal immunochemical test (FIT), the primary colorectal cancer (CRC) detection technique, with the fecal DNA (F-DNA) test which has been recommended as an alternative to FIT as the standard of care. METHODS: A hybrid decision tree-Markov model was created to estimate the CRC screening cost per quality-adjusted life-year (QALYs) of using the FIT annually, or the F-DNA every 3, or the F-DNA every 5 years in individuals at average CRC risk from a third-party payer's perspective. a hypothetical cohort of 10,000, 50-year-old individuals transitioning between the health states: healthy, polyps <10 mm, polyps >10 mm, local cancer, regional cancer, advanced cancer, and dead, were followed until they were 75 years. Colonoscopy followed every positive test result. Sensitivity, specifi city, transition probabilities, and costs (in 2010 US Dollars) were obtained from clinical trials and published peer-reviewed articles. The costs and QALYs were discounted at 3% and sensitivity analyses were conducted. RESULTS: Using FIT annually would result in an average cost of $56,716.94/QALY for each individual with an incremental cost-effectiveness ratio (ICER) of $76,181/
treatment. The aim of this study was to compare the cost-effectiveness of extra-corporeal photopheresis (ECP) with Rituximab (Rmb) or Imantinib (IMT) or pooled comparators (pooled) in addition to the usual care of cGvHD after standard treatment failure in Spain. METHODS: The model assessed the incremental cost-effectiveness ratio (ICER) of ECP versus Rmb or IMT or pooled comparator. The incremental cost and quality-adjusted life-year (QALY) gained were estimated using a short-term decision analysis and a long-term Markov cohort modeling approach. Model probabilities were obtained from literature, while treatment pathways and adverse event where derived from expert opinion. Local data on health resources use and costs were used and validated by clinical experts. The time horizon of the study was 5 years and only direct local medical costs (euros 2010) were considered. a probabilistic sensitivity analysis was performed. RESULTS: Preliminary results show that the higher effi cacy of ECP leads to a gain of 0.19-0.20 QALY at fi rst year and 0.15-0.19 at year 5 when compared to Rmb or IMT or pooled. The short-term cost of ECP is higher than Rmb (c2.900), IMT (c800) and pooled (c1.800). The ICER results for ECP for the fi rst year were c15,340 versus RMB, c3.663 verus IMT and c8.977 versus pooled. At 3 years, ECP was dominant versus IMT and pooled, and showed ICER less than c3.000 vs. Rmb. The results of the evaluation were sensitive to limited data available. CONCLU-SIONS: Preliminary results of this study indicate ECP is a cost-effective, below the Spanish threshold, or dominant option with respect altenatives.
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COST-EFFECTIVENESS OF OCTREOTIDE LAR IN PATIENTS WITH METASTATIC NEUROENDOCRINE MIDGUT TUMORS FROM THE PRIVATE PAYER PERSPECTIVE IN BRAZIL
Takemoto ML 1 , Fernandes RA 1 , Chinen R 2 , Alves MR 2 1 ANOVA-Knowledge Translation, Rio de Janeiro, RJ, Brazil; 2 Novartis Pharmaceuticals, São Paulo, SP, Brazil OBJECTIVES: Octreotide LAR has shown antiproliferative activity in advanced midgut neuroendocrine tumors (NET) increasing time to tumor progression (TTP) compared to placebo. This study aims to assess the costs and consequences of OCT-LA versus best supportive care (BSC) in patients with metastatic midgut NET from the private payer perspective. METHODS: A three health state (progression-free survival, progression, and death) Markov model with a 10-year time horizon was developed with data from the phase III PROMID trial. Within the trial, subjects remained on treatment until progression. Resource use was estimated through published data and input from clinical experts to refl ect clinical practice in the Brazilian private setting. Unit costs were obtained from Brazilian offi cial sources. Costs and outcomes were discounted 5% per annum. RESULTS: The model estimated 14 months PFS with OCT-LA versus 6 months with BSC. Estimated PFS gain was 0.60 years (1.07 vs. 0.46). Total cost of treatment was 275,497 BRL for BSC and 303,111 BRL for OCT-LA. The incremental cost per progression-free year gained was 28,706 BRL in the OCT-LA arm versus BSC due to treatment until progression. The mean cost of supportive care for progressive disease represented 87.3% (239,883 BRL) and 76.9% (224,388 BRL) of the fi nal cost of treatment for BSC and OCT-LA, respectively. Results remained consistent when univariate sensitivity analyses were run. CONCLU-SIONS: OCT-LA is a clinically effective option to control tumor growth in patients with metastatic midgut NET. OCT-LA provides longer TTP compared to BSC for those patients. Although there is ecological evidence to suggest improvement in OS after introduction of OCT LA, the ICER for an additional life-year gained is not currently calculable as the PROMID trial was not designed to evaluate OS. Further areas of research to elucidate the association between PFS and OS in NET are needed.
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OST-EFFECTIVENESS ANALYSIS OF ADJUVANT THERAPY WITH IMATINIB MESYLATE IN PATIENTS AFTER RESECTION OF LOCALIZED PRIMARY GASTROINTESTINAL STROMAL TUMOR
Krysanov I, Zorin N, Pyadushkina E, Koval DA Institute of Clinico-Economic Expertise and Pharmacoeconomics, RSMU, Moscow, Russia OBJECTIVES: Imatinib is a low molecular tyrosine kinase inhibitor that blocks the kinase activity KIT and PDGFRα, and a fi rst-line drug in the treatment of unresectable and metastatic gastrointestinal stromal tumor (GIST). The standard treatment of patients with localized primary GIST is a complete surgical resection of the tumor. Several studies have shown that target therapy improves survival of patients after GIST resection. The purpose of this study was to estimate the costs and effectiveness of adjuvant imatinib therapy versus no treatment in patients who have undergone GIST resection. METHODS: A Markov model was used to estimate costs and effectiveness of adjuvant imatinib therapy in the long-term follow-up period. Data on overall and recurrence-free survival were taken from the phase III clinical trial ACOSOG Z9001 and were used to assess effi cacy. Measures of effectiveness include such indicators as life-years saved and quality-adjusted life-years (QALYs) gained for adjuvant imatinib following surgical resection and surgical resection only. Data on the common practice of GIST treatment in the Russian oncology centers were used in the model. Costs, life-years, and QALYs gained were calculated over the 50-year time horizon and discounted at an annual rate of 5%. RESULTS: The number of life-years saved was 10.01 for imatinib treatment against 8.67 for no treatment. The number of QALYs was 7.97 and 6.82, respectively. The costs of 1-year patient management with adjuvant imatinib therapy were c44,348 per person; a patient who had not received imatinib in adjuvant mode required c32,102 per person. CONCLUSIONS: The analysis showed that adjuvant imatinib therapy is more costly compared with no treatment. However, it is more effective and can increase the life expectancy of patients. In this
